MHRA’s annual registration fee structure is reshaping dental lab budgets
From April 2026, MHRA introduced a new annual charging structure for medical device registration that will be felt directly by manufacturers, including dental laboratories that place regulated products into the system. The fee model is simple on paper and difficult in practice: £300 each year for every chargeable GMDN Level 2 category, or Level 1 where no Level 2 exists. For laboratories that work across multiple product types, the cumulative bill can rise quickly.
The change lands at a time when many dental laboratories are already operating in a narrow commercial margin. Compliance costs rarely arrive as a single dramatic event. They accumulate through registration work, classification reviews, documentation updates, staff time, and the need to maintain regulatory oversight across products that may sit in more than one category. A flat annual charge multiplied across several device groupings can alter the economics of routine registration in a way that is especially difficult for smaller businesses to absorb.
The financial strain is not just about the number on the invoice. It is also about how devices are classified, because classification determines which categories are chargeable and how many annual fees a manufacturer must carry. In a sector where product lines can be highly specialised, even modest uncertainty over category assignment can create a disproportionate cost burden.
Category clarity mattered before the first fee was paid
When the new system was introduced, uncertainty over how dental devices should be categorised created an immediate compliance problem for laboratories. Very little dental-specific guidance was available, leaving some businesses without a clear route to decide which categories applied to their products. In regulatory terms, ambiguity is expensive. It can lead to over-registration, under-registration, or repeated queries that consume time and resources before a product is even fully mapped to the fee structure.
The DLA worked with the MHRA to obtain clarification and help members understand which categories applied to their products. That step reduced the risk of unnecessary financial exposure for many laboratories. It also shows how heavily the practical burden of regulation depends on sector-specific interpretation, not simply on the wording of the fee schedule itself.
For dental labs, the issue is not abstract administration. Fee categorisation shapes whether a product is treated as a single regulated item or folded into several chargeable device groupings. Where a laboratory makes multiple products, or where a product sits near the boundary of more than one classification, the annual cost can multiply in ways that are difficult to predict from the headline fee alone.
This is one reason registration changes can have outsized effects in smaller clinical manufacturing environments. A business with a large portfolio can spread the compliance overhead more easily than a laboratory with a limited number of products and a tighter margin structure. In the latter case, each additional category is not just a regulatory label; it is a recurring expense.
A £300 fee becomes a broader cost multiplier across product lines
The new annual charge is not a one-off administrative fee. It is a recurring obligation attached to every chargeable category, which means the long-term cost profile depends on the breadth of a laboratory’s product range. For a manufacturer with only a small number of devices, the fee may be manageable. For a lab with a broader portfolio, the cost can rise in a way that feels disconnected from the actual size of the business.
That matters because dental laboratories often serve a specialised clinical niche rather than a mass-market one. Their products may be highly tailored to individual patient needs or to specific restorative workflows. In that setting, a broad-brush charge structure can penalise diversity of output, since the number of registrations may expand faster than revenue. The more finely a product line is segmented for regulatory purposes, the more recurring fees a laboratory may face.
Compliance teams will also have to keep pace with ongoing category interpretation. Once a classification is accepted, it still needs to be maintained, monitored, and reconciled against product changes. If a device evolves, the regulatory mapping may shift with it. The fee structure therefore creates not only a direct cost, but an administrative discipline that has to be sustained year after year.
For some laboratories, that will mean revisiting how product portfolios are organised. For others, it may mean more careful scrutiny of whether certain items truly require separate category treatment or whether they can be grouped legitimately within the rules. Either way, the fee structure turns classification into a commercial issue as well as a regulatory one.
Dental regulation now sits closer to the balance sheet
The wider significance of the MHRA change is that registration has moved closer to the centre of business planning. Regulatory compliance has always carried a cost, but annual charging makes that cost more visible and more immediate. Once a laboratory knows that every chargeable category triggers a recurring fee, registration is no longer just a background requirement. It becomes part of the forecast.
That shift has a practical consequence for patient-facing work, too. Dental laboratories are not simply administrative entities; they are part of the supply chain that supports restorative and prosthetic care. When compliance costs rise, laboratories may feel pressure in staffing, pricing, turnaround planning, or product prioritisation. None of those effects are guaranteed, but the commercial mechanism is straightforward: higher overheads tighten the room to manoeuvre.
The clarification obtained through DLA engagement with MHRA therefore has more than a bookkeeping value. It helps laboratories avoid unnecessary exposure at a time when the fee model could otherwise have imposed a larger burden than intended. Regulatory certainty does not remove the cost, but it can stop the cost from becoming inflated by misclassification.
The deeper problem remains the same. A fee structure that is easy to describe can still be hard to absorb when it is applied across multiple categories, multiple products, and multiple years. Dental laboratories will now need to treat registration planning as an ongoing financial task, not a one-time compliance exercise. The unresolved issue is how many businesses can carry that burden without having to rethink the scope of what they manufacture.